NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Technology Appraisal

Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

Provisional stakeholder list of consultees and commentators

 Company Merck Sharp & Dohme (pembrolizumab) All Wales Therapeutic and Toxicology Centre Allied Health Professionals Federation Balack Health Agency British Lung Foundation Cancer Black Care Cancer Black Care Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Cancer Physicians Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO - The Association for Cancer Surgery British Institute of Radiology British Psychosocial Oncology Society British Thoracic Concology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK 	Consultees	Commentators (no right to submit or
 Merck Sharp & Dohme (pembrolizumab) Patient/carer groups Black Health Agency Brittish Lung Foundation Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation South Asian Health Foundation Sopecialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO - The Association for Cancer Surgery British Geriatrics Society British Thoracic Oncology Group British Thoracic Society British Thoracic Society Cancer Research UK National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK All Wales Therapeutic and Toxicology Centre Allied Health Professionals Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Accord Healthcare (cisplatin, carboplatin, earboplatin, gemcitabine) Healthcare Improvement Scotland Medicines and Public Safety for Northern Ireland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Heart and Lung Institute Medicines Care National Pharmacy Association Scottish Medicines Consortium<th></th><th>appeal)</th>		appeal)
Patient/carer groups Black Health Agency British Lung Foundation Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Thoracic Oncology Group British Thoracic Oncology Group British Thoracic Society Primary Care Respiratory Society UK Alicinal Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Patient Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Health Cancel Madicines and Health Cancel National Association of Primary Care National Pealth Cauching Medicines and Health Cauching Medicines and Heal	<u>Company</u>	General
 Allied Health Professionals Federation Black Health Agency British Lung Foundation Cancer Black Care Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Institute of Radiology British Psychosocial Oncology Society British Thoracic Society British Thoracic Concology Group British Thoracic Society British Institute of Radiology British Thoracic Society British Thoracic Society British Thoracic Society British Thoracic Society British Institute of Radiology British Carlative Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Medicines and Public Safety for National Association of Primary Care NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Councils Mealthcare	 Merck Sharp & Dohme 	All Wales Therapeutic and
 Allied Health Professionals Federation Black Health Agency British Lung Foundation Cancer Black Care Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Institute of Radiology British Psychosocial Oncology Society British Thoracic Society British Thoracic Concology Group British Thoracic Society British Institute of Radiology British Thoracic Society British Thoracic Society British Thoracic Society British Thoracic Society British Institute of Radiology British Carlative Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Medicines and Public Safety for National Association of Primary Care NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Councils Mealthcare	(pembrolizumab)	Toxicology Centre
 Black Health Agency British Lung Foundation Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Regiatrics Society British Roeriatrics Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Medicines and Health, Social Medicines and Healthcare Products Regulatory Agency National Association of Primary Care NHS Alliance NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Accord Healthcare (cisplatin, carboplatin, earboplatin, earboplatin, gemcitabine) Bristol-Myers Squibb Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pocha (atexplizumab) (subject to 	,	Allied Health Professionals
 Black Health Agency British Lung Foundation Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Regiatrics Society British Roeriatrics Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Medicines and Health, Social Medicines and Healthcare Products Regulatory Agency National Association of Primary Care NHS Alliance NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Accord Healthcare (cisplatin, carboplatin, earboplatin, earboplatin, gemcitabine) Bristol-Myers Squibb Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pocha (atexplizumab) (subject to 	Patient/carer groups	Federation
 British Lung Foundation Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Thoracic Oncology Group British Thoracic Society British Thoracic Society Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		Board of Community Health Councils
 Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Marmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Rational Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		<u> </u>
 Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Pealthcare Products Regulatory Agency National Association of Primary Care NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Healthcare (cisplatin, carboplatin, earboplatin, earboplatin, gemcitabine) Bristol-Myers Squibb Hospira UK (cisplatin, carboplatin, gemcitabine) Hilly UK (gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		British National Formulary
 Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation Specialised Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society British Cancer Research UK National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK 	Cancer Equality	
 Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Concology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Association of Primary Care NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Professional groups Accord Healthcare (cisplatin, carboplatin, carboplatin, etoposide, gemcitabine) Hospira UK (cisplatin, carboplatin, gemcitabine) Professional groups Accord Healthcare (cisplatin, carboplatin, gemcitabine) Hospira UK (cisplatin, carboplatin, gemcitabine) Professional groups Accord Healthcare (cisplatin, carboplatin, gemcitabine)<		
 Macmillan Cancer Support Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Medicines and Healthcare Products National Association of Primary Care National Pharmacy Association Scottish Medicines Consortium Welsh Health Specialised Services Committee Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine) High Thoracic Concology Group High Thoracic Oncology Group High Thoracic Oncology Group High Thoracic Society Hospira UK (cisplatin, carboplatin, gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Prophe (atazolizumah) (subject to Prophe (atazolizumah) (subject to 		<u>'</u>
 Maggie's Centres Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Association of Primary Care National Association of Primary Care National Health Care Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Fharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Care (sisplatin, carboplatin, carboplatin, carboplatin, carboplatin, gemcitabine) Healthcare Improvement Scotere NASO-Improvement Scotere NASO-Improvement Scot		
 Marie Curie Muslim Council of Britain Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Healthcare Products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	• •	
 Muslim Council of Britain Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Thoracic Oncology Group British Thoracic Society British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pgeche (stezolizumab) (subject to 		
 Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Thoracic Oncology Group British Thoracic Society British Thoracic Society Cancer Research UK National Lung Cancer Forum for Nurses Primary Care National Association of Primary Care National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irrinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pgeche (atexplizumab) (subject to 		
 South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Pharmacy Association NHS Alliance NHS Confederation Welsh Health Specialised Services Committee Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		
 Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Scottish Medicines Consortium Welsh Health Specialised Services Committee Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK 		
 Tenovus Cancer Care UK Lung Cancer Coalition Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		II
 UK Lung Cancer Coalition Drofessional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Thoracic Oncology Society British Thoracic Society British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Scottish Medicines Consortium Welsh Health Specialised Services Committee Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pfizer (carboplatin, cisplatin, carboplatin, gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, cisplatin, gemcitabine)	•	
 Welsh Health Specialised Services Committee Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Welsh Health Specialised Services Committee Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Possible comparator companies Accord Healthcare (cisplatin, carboplatin, carboplatin, gemcitabine) Hospira UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		_
 Professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Committee Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	UK Lung Cancer Coalition	_
 Association of Cancer Physicians Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		·
 Association of Respiratory Nurse Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Possible comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		Committee
 Specialists BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	•	
 BASO – The Association for Cancer Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK carboplatin, etoposide, gemcitabine, irinotecan) Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	·	
 Surgery British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	•	` · ·
 British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Bristol-Myers Squibb Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	 BASO – The Association for Cancer 	
 British Institute of Radiology British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Pharmaceuticals limited (etoposide) Hospira UK (cisplatin, carboplatin, gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Primary Care Respiratory Society UK Poche (atezolizumab) (subject to generation) 	Surgery	,
 British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Hospira UK (cisplatin, carboplatin, gemcitabine) Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	 British Geriatrics Society 	· ·
 British Thoracic Oncology Group British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Roche (atexolizumab) (subject to process) 	 British Institute of Radiology 	` ' '
 British Thoracic Oncology Group British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	 British Psychosocial Oncology Society 	· · · · · · · · · · · · · · · · · · ·
 British Thoracic Society Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Lilly UK (gemcitabine) Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 		,
 Cancer Research UK National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Medac GmbH (etoposide, gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) Roche (atexolizumab) (subject to gemcitabine) 		,
 National Heart and Lung Institute National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK gemcitabine) Pfizer (carboplatin, cisplatin, gemcitabine) 	,	
 National Lung Cancer Forum for Nurses Primary Care Respiratory Society UK Primary Care Respiratory Society UK Prizer (carboplatin, cisplatin, gemcitabine) 		,
Primary Care Respiratory Society UK Roche (atezolizumah) (subject to	o	,
' ' ' ' A Rocha (atazolizilmah) (subject to	•	
Royal College of General Practitioners 100010 (ato20112411145) (346)2011	 Royal College of General Practitioners 	Roche (atezolizumab) (subject to

Provisional stakeholder list for the proposed technology appraisal of pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509. Issue date: December 2019

Consultees	Commentators (no right to submit or appeal)
 Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England NHS Southend CCG NHS Tameside and Glossop CCG Welsh Government 	NICE appraisal) Sandoz (cisplatin) Sun Pharma (gemcitabine) Teva (carboplatin, cisplatin) Relevant research groups British Association of Lung Research Cochrane Airways Group Cochrane Lung Cancer Group Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Cancer Research Institute National Cancer Research Network National Institute for Health Research Associated Public Health Groups Public Health England Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Provisional stakeholder list for the proposed technology appraisal of pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509. Issue date: December 2019

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Provisional stakeholder list for the proposed technology appraisal of pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509. Issue date: December 2019

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.